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Abstract 
Few studies have empirically examined the relationship between trust and its consequences in 
the pharmaceutical context (e.g. the consequences of trust in medicines advice for patient 
behaviour). This study empirically examined the European public’s perceived trustworthiness 
of medical, societal, and industry sources of medicines advice, and its consequences for their 
behavioural intentions including their medicine-taking and information-seeking behaviour. A 
representative survey (N=6,001) was conducted with adults from six European countries: Great 
Britain, France, Germany, Denmark, Italy, and Poland. As expected, respondents consistently 
rated advice from medical sources (GPs, pharmacists, local hospitals, emergency services) as 
significantly more trustworthy than advice from societal sources (the Internet, friends/relatives, 
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and the mass media) and, especially, industry (pharmaceutical companies and brand specific 
websites). A structural equation model then revealed strong associations between the public’s 
perceived trustworthiness of these medical, societal, and industry sources and their medicine-
taking and information seeking intentions. Important national variations were found including 
in the public’s opinions on when authorities should convey new safety information. 
Implications for communicating benefit-risk information in a more transparent regulatory 
environment are discussed, including the importance of maintaining and strengthening trust in 
medical actors and committing more resources to supporting national risk communication. 
 






A raft of risk communication research has examined the strength of the relationship between 
public trust and its consequences for risk perception, risk acceptance, and behavioural 
intentions (see Earle, 2010: 565-567 for a discussion; Slovic, 1993, 2000; Earle and 
Cvetkovich, 1995; Sjöberg, 1999, 2001; Siegrist et al. 2007; Eiser et al. 2015; Poortvliet and 
Lokhorst, 2016). The trust-consequence relationship is influenced by contextual factors with 
strong correlations being found between trust and, for instance, an individual’s knowledge of 
a hazard and agreement on hazard-related values (Siegrist et al. 2007; Earle, 2010). 
 
Research on the trust-consequence relationship has particularly focused on environmental/ 
technological and food safety risk management contexts such as nuclear power, nuclear waste, 
and genetically modified organisms (GMOs). In contrast, few empirical studies on trust and its 
consequences have been conducted in the European pharmaceutical context (Bouder et al. 
2015). A systematic review of 129 academic articles on health information seeking published 
from 1978 to 2010 revealed that only 8.5% of the sample included any measure of information 
or source credibility (of which trust was considered a sub-category) (Anker et al. 2011).  
 
Despite this dearth of research, pharmaceutical regulators on both sides of the Atlantic have 
made (re)gaining trust a top priority over the past ten years or so (Hamburg and Sharfstein 
2009, EMA 2015). There is a pressing policy need to examine empirically the trust-
consequence relationship in this understudied context. For instance, Tustin (2010) reveals that 
trust in different sources for medical information can affect the extent to which patients comply 
with treatment plans. Furthermore, the EU’s pharmaceutical regulator, the European Medicines 
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Agency (EMA), needs more rigorous empirical evidence to inform its strategy of building 
public trust (Eichler et al. 2009, 2012; Löfstedt and Bouder, 2014; Way, 2017). 
 
(1.1) Trust and its consequences 
 
Although there are competing definitions and types of trust (e.g. general, interpersonal, 
institutional), Siegrist and Cvetkovich (2000: 354) define social trust as “the willingness to rely 
on those who have the responsibility for making decisions and taking actions related to the 
management of technology, the environment, medicine, or other realms of public health and 
safety”. Two comprehensive literature reviews have shown the complexity and diversity of the 
relationship between behaviour and trust including papers dedicated solely to definition as well 
as on dimensions, forms, heuristics, and models (Siegrist et al. 2008; Earle, 2010; Tuler and 
Kasperson, 2014). In multi-actor environments, such as the pharmaceutical context, this 
includes various individuals (e.g. medical doctors and pharmacists), institutions (e.g. 
pharmaceutical companies, and regulatory bodies), and groups (e.g. patient representatives) 
that are intimately involved in directly and indirectly communicating benefit-risk medicines 
information to the public (Way et al. 2016).  
 
One notable research puzzle centres on the relationship between trust in individuals, 
institutions, and groups and its consequences for benefit perception, risk acceptance, affective 
responses, behavioural intentions, and others (Earle, 2010). In a seminal article, Paul Slovic 
(1993) emphasised the importance of trust, noting that high public concern about a risk is 
associated with high perceptions of risk, low benefits, and are viewed as unacceptable (e.g. 
nuclear power, pesticides or industrial chemicals). Vice versa, low public concern about a risk 
is associated with low perceptions of risk, high benefits, and are viewed as acceptable (e.g. X-
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rays) (Slovic, 1993: 676). In light of these observations, a wave of empirical studies have since 
examined the relationship between trust and its consequences for various risks including 
nuclear waste (Mushkatel and Pijawka 1992; Tuler and Kasperson, 2014), gene technology 
(Siegrist, 1999, 2000), carbon capture and storage (Midden and Huijts, 2009), the 2010 ash 
cloud crisis (Eiser et al. 2015), genetically modified products (Gaskell et al. 1999; Frewer et 
al. 2003), and electro-magnetic fields such as from mobile phones and base stations (Siegrist 
et al. 2003,  2005). For example, after conducting four empirical case studies on trust in 
different risk management contexts, Löfstedt (2005) concluded that if there were high levels of 
public trust toward authorities, there would be low levels of public perceived risk; inversely, if 
there were high levels of public distrust toward authorities there would be higher levels of 
public perceived risk (also see Löfstedt, 1995). 
 
One of the main conclusions from this research has been the importance of context in 
determining the strength of the relationship between trust and its consequences (Earle et al. 
2007; Poortvliet and Lokhorst, 2016). Although there has been heated debate (e.g. Sjöberg, 
1999, 2001; Slovic, 2000), a comprehensive review of the literature (Earle et al. 2007) found 
that “the relation between trust and risk perception […] is contingent upon certain contextual 
factors”. Factors such as hazard knowledge and agreement on hazard-related values are known 
to be critically important in contributing to whether high/ low trust will strongly, moderately, 
or weakly influence public perceptions of risk (Earle et al. 2007; Earle, 2010). 
 
Despite risk scholars acknowledging the importance of context, trust research has been 
dominated by studies examining environmental/ technological and food safety risks (Siegrist 
et al. 2007; Löfstedt and 6: 2008). In contrast, research on trust in the medical area has evolved 
separately with scholars, until recently (Holt et al. 2016), focusing on individual patients and 
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their trust in physicians and their advice (Löfstedt and Perri 6, 2008; Edwards and Elwyn, 
2009). In a separate study on trust in online sources of medical information, Tustin (2010) 
found that patient compliance with physicians’ treatment plans was lower if they trusted 
Internet sources of medical information; patients were found to turn to Internet sources due to 
dissatisfaction with their healthcare providers. Aside from these few isolated studies, trust in 
the medical/ pharmaceutical context has been largely overlooked by risk scholars and 
conceptualised narrowly by medical scholars and practitioners. Yet, there are many reasons 
why the European pharmaceutical context is likely to influence the relationship between trust 
and its consequences beyond the doctor’s office. This includes the public having particularly 
low levels of trust in pharmaceutical companies and low knowledge of the organisations that 
monitor and evaluate medicines such as EMA (Bouder et al. 2015). 
 
While specific research on trust and behaviour in the pharmaceutical sector has been scarce, a 
number of conceptions have flourished, which neglect non-pharmaceutical research outcomes. 
A crucial assumption among pharmaceutical researchers, observers and opinion leaders is that 
making vast quantities of information available to all under the concept of “transparency” 
would (re)build public trust in the scientific pharmaceutical evaluation system (Gøtzsche and 
Jørgensen, 2011; Passarani, 2010; Rodwin and Ambramson, 2012; Goldacre, 2012; Doshi et 
al. 2012; O’Reilly, 2015; Willmott, 2014, 2016). Research in non-pharmaceutical sectors, 
however, does not indicate an automatic link between greater transparency and trust/credibility 
building. Research from the Netherlands, for example, indicates that the reverse may actually 
be the case. The more transparent regulators and authorities become, the more the public 
actually see how policy makers apparently muddle through and bicker throughout the decision-
making process (Lindbloom 1959; Stone, 2012), the more disenchanted they become with it 
(Bovens and Wille 2008; Grimmelikhuijsen 2010). In other words, the perceived 
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trustworthiness of regulators and policy makers are more or less based on pre-existing views 
of the government as a whole (Van De Walle 2004), and as the public receive more information, 
they are able to change their judgments based on increasingly accurate knowledge, which in 
many cases becomes rather more critical of the policy makers themselves (Mandak et al. 2007). 
 
In the context of risk communication science, evaluating the evidence behind these claims is 
important in two related ways. As Fischhoff et al. (2011) note: 
 
“One is that communications should be consistent with the science- and not 
do things known not to work nor ignore known problems. The second is 
communications should be evaluated-because even the best science cannot 
guarantee results. Rather, the best science produces the best-informed best 
guesses about how well communications will work. However, even these 
best guesses can miss the mark, meaning that they must be evaluated to 
determine how good they are and how they can be improved.” [23:2]. 
 
At the time of writing, there is no sign that key players in the sector, and chiefly the EMA have 
taken stock of possible negative impacts of untested measures introduced with the aim of 
increasing public trust. The EMA, for instance has neither undertaken nor announced plans to 
undertake a systematic review of its “landmark” transparency policies and/or trust in the 
pharmaceutical evaluation system (EMA 2014, 2016, 2018a)1. Rather, the vast majority of 
studies conducted by ‘outsiders’ such as medical scholars, data-miners, industry, and non-
governmental organisations have focused on anecdotal evidence or provided some empirical 
                                                 
1 While the agency has introduced a biennial survey of its closest stakeholders (EMA, 2017), EMA has 
not conducted research on its transparency policies or public trust. 
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evidence from the perspectives of external researchers wanting to re-use medicines data, such 
as on the accessibility and assessability of documents (Gøtzsche and Jørgensen, 2011; Chan et 
al. 2014; Goldacre, 2012; Doshi et al. 2013; Doshi et al. 2016). Recently, a handful of empirical 
studies have also explored the implications of the regulator’s policies for communicating about 
the benefits and risks of medicines with the public, patients, and medical doctors in experiments 
(Lofstedt and Way, 2016a, 2016b) and surveys (Way et al. 2016; Bouder et al. 2015). Yet, few 
empirical studies on public trust in the European pharmaceutical system have been conducted. 
Therefore, this study provides empirical evidence that seeks to support EMA’s transparency-




The study set-out to measure the public’s perceived trustworthiness of ten medical, societal 
and industry ‘sources’2 of medicines advice (i.e. medicines communication channels) (see Box 
1). In turn, the relationship between these measures of perceived trustworthiness and its 
consequences for the public’s behavioural intentions3 were examined.  
 
The 10 medical, societal and industry sources were selected because past studies have 
identified these non-regulatory communication channels as important ‘go-betweens’ between 
key information sources and audiences such as EMA and patients, respectively (Dunwoody 
and Griffin, 2014; Bouder et al. 2015). The 10 sources or ‘communication channels’ act as key 
“conveyance devices that collect information from [another] source or sources, repackage it 
                                                 
2 Some scholars make an important distinction between sources and channels (see Dunwoody and Griffin, 
2014). From the public’s perspective, however; information channels are more commonly referred to as 
sources. Therefore, communication channels and sources are referred to interchangeably in this study. 
For example, a doctor or pharmacist might be a source of medicines advice from the public’s perspective 
even though they can be categorised, from a system’s level perspective, as communication channels. 
3 The public’s perceived likelihood of engaging in a given behavior.  
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and then disseminate it” (Dunwoody and Griffin, 2014). For example, doctors receive 
information from sources such as the regulators, medical journals and colleagues and, in turn, 
provide medicines advice to patients.  
 
An alternative approach might have been to examine public trust in EMA and/or the public’s 
domestic regulatory authorities. However, this would have been less meaningful, as past 
research has consistently shown that most Europeans have not heard of the concrete entities 
that regulate medicines in Europe (Bouder et al. 2015). Indeed, it would not be useful to 
measure the public’s trust in entities that they are not even aware exists. The authors also 
wanted to advance understanding of the effects of trust beyond trust in large institutions, to 
trust in the full range of actors, including medical, societal and industry sources. 
 
Box 1: Public sources of medicines advice grouped into three main categories 
Category Source of Medicines Advice 
Medical General Practitioners (GPs); Pharmacists; Local Hospitals; Emergency Services; 
Medical Journals 
Societal The Internet (in general); Mass Media (newspapers, television, radio, etc.); 
Friends or relatives 
Industry Pharmaceutical Companies (including websites); Brand-Specific Websites (of 
specific medicines) 
 
Before conducting empirical investigations (Section 2), three hypotheses were developed based 
on the foregoing literature and the authors’ previous empirical research on risk communication 
and transparency in the sector (Bouder et al. 2015; Löfstedt et al. 2015; Löfstedt and Way 
2016a, 2016b; Way et al. 2016). The main dependent variable in our analysis is our survey 
respondents’ answers to what action they would take if confronted with information about a 
potential problem with a medicine they are taking. We examine whether or not survey 
respondents indicate a behavioural intention to continue taking their medicine as usual whilst 
seeking additional information.  The two actions brought together in this variable are important; 
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best medical advice would be for patients to not discontinue taking a prescribed medicine, 
unless told to do so explicitly by a relevant medical authority. Nevertheless, actively seeking 
additional information would be the best way to clarify whether a problem does or does not 
exist.  Most healthcare professionals and regulatory agencies would recommend that patients 
continue taking their medicine (as prescribed by their doctor) and seek additional advice if they 
receive uncertain adverse medicines information (i.e. after receiving information pointing to a 
safety problem via letter, telephone, e-mail etc.) (e.g. NHS Choices).  For this study, the authors 
chose to examine the behaviour that would be recommended by medical experts rather than 
making a subjective value judgement (e.g. NHS Choices, 2019). 
 
We sought to associate trust specifically with information seeking and compliance behaviour 
because of tentative links that have been suggested, but not verified, between these three 
variables in literature on health information seeking.  Although notable amounts of health 
information seeking occurs via both online and offline sources across European nations 
(Reifegerste et al. 2017), a large majority of research on health information seeking examines 
information specifically from online sources (e.g., Ayers and Kronenfeld 2007; Cline and 
Hayes 2001; Fergie et al. 2016; Gray et al. 2005; Lee et al. 2015; Percheski and Hargittai 2011; 
Powell and Clarke 2006).  Some of this work on Internet information seeking reveals higher 
trust in traditional (offline) sources (Khoo et al. 2008).  It also contends that seeking 
information online can improve or harm patient-physician relationships, depending on whether 
the patients then discuss the new online information with their physicians and on the strength 
of the patients’ prior relationship with physicians (Broom 2005; Hay et al. 2008; Stevenson et 
al. 2007; Tan et al. 2017).  Further, research suggests that information seeking online can lead 
to non-compliance in following recommended treatment, particularly in individuals with high 
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anxiety, diminishing health, and who perceive Internet health information to be important 
(Weaver et al. 2009).   
 
The dynamics between physicians and the Internet as information sources suggests that 
evaluations of these two sources of information could shape both information seeking and 
compliance with prescribed treatment.  Although there is nuance to the relationships in the 
aforementioned research, use of and perceived value in Internet information seems it could 
diminish compliance, whilst use of and perceived value in doctors would increase compliance.  
When presented with adverse information about a medicine, patients who trust primarily in 
physicians would follow physician advice and seek more information from medical sources to 
further their understanding of the issue, whilst patients who trust primarily non-medical 
Internet sources would have more cause to reject the treatment and seek information from 
Internet sources that could further increase scepticism (Tan et al. 2017, Tustin 2010).  The 
literature in this area, however, does not extend much beyond looking at doctors and the 
‘Internet’.  There are many forms of online information and many types of medical advice 
beyond one’s primary care physician.  Therefore, in our study, we include a wider range of 
sources of medical and societal information, and we add pharmaceutical industry sources due 
to our focus on behaviour related to specific medicines. 
 
Our three hypotheses centre on the direct effects of the public’s trustworthiness of medical, 
societal and industry sources and their behavioural intentions (Box 2, and see Figure 1 for the 
hypothesised pathways). We offer these hypotheses due to the expectation that medical sources 
would support the aforementioned best medical practice, that societal sources would raise 




Box 2: Hypotheses on the direct effects of trustworthiness in a safety scenario. 
H1 Higher trustworthiness of medical sources will directly predict greater propensity for 
the public to continue to take their medicine as usual and seek additional information.   
H2 Higher trustworthiness of societal sources will directly predict diminished propensity 
for the public to continue to take their medicine and to seek additional information. 
H3 Higher trustworthiness of industry sources will directly predict greater propensity for 
the public to continue to take their medicine and to seek additional information. 
 
 
Figure 1: Model displaying the study’s hypotheses about the relationship between public trust in medical, societal 











The data for this study originates from a survey conducted by the authors in November 2015. 
A random quota sample was obtained with 6,001 respondents aged 18-64 from Great Britain 
(N=1,000), France (N=1,000), Germany (N=1,000), Denmark, (N=1,001), Italy (N=1,000), 
and Poland (N=1,000). The sample was nationally representative for gender by age, where 
respondents live by region, and whether they are in work or not based on 2013 figures from 
Eurostat (Appendix A). Further demographic information was also collected for income, 
educational qualifications, and ethnicity/parents nationality (Appendix A). In addition, data 
from three countries surveyed in November 2013 by Bouder et al. (2015) was used to enable 
cross-sectional comparisons over time4. In 2012, a random quota sample was obtained with 
3,083 respondents aged 18-64 from 3 repeated countries: Great Britain (N=1,014), France 
(N=1,061), and Germany (N=1,008). The 2012 sample was nationally representative for gender 
by age, where respondents live by region, and whether they are in work or not, based on 2012 
figures from Eurostat, the official statistics office of the European Commission (see Bouder et 
al. (2015) for further 2012 sample information). All investigations were carried out in 
accordance with Maastricht University rules on ethical approval, where Bouder was based 
when the survey was conducted. 
 
Both 2012 and 2015 respondents were recruited by Ipsos, a UK polling agency, through online 
panels and quota sampling. Large and varied sets of panel participants were first obtained 
                                                 
4 Bouder et al.’s (2015) original study included 6 rather than 3 EU countries with a total of 5,648 
respondents. However, only three countries are relevant to this paper. 
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through email lists, banners, websites, text ads, search engine methods, and other techniques. 
The agency then invited prospective respondents from these panels. Incentive points were 
offered to respondents – a common form of incentive for participants in online panel surveys 
– which helped reduce potential for response bias (Dillman, 2007). Notably, Ipsos has strict 
procedures and industry standard checks to preserve panel quality such as mechanisms to 
discourage professional responders and continually refresh respondents between surveys5. 
 
In the 2015 survey, response rates were calculated based on the number of invites sent, the 
number of incomplete interviews due to having a full quota and respondents screening out, and 
the number of completed interviews (see Bouder et al. (2015) for rates in 2012). They were 
10.8% (GB), 13.3% (France), 14.6% (Germany), 8.5% (Denmark), 26.1% (Italy), and 10.4% 
(Poland) (see Appendix C for more details). These response rates can be considered as 
conservative estimates due to the nature of the recruitment process. Ipsos sent out a large 
number of invitations to its panels, but then established a quota for the number of respondents 
it accepted to ensure representativeness. Up to 100% of panellists could therefore have tried to 




The survey instrument was created in 2012 (Bouder et al. 2015) and only minor alterations 
were made for 2015 (Appendix B). First, additional follow-up questions were added to the 
2015 questionnaire for 3 questions that produced the most interesting/important results in 2012. 
Second, a few questions were removed from the 2012 questionnaire to ensure the average 
                                                 
5 For more information on Ipsos’s procedures please visit www.ipsos-mori.com or Ipsos MORI (2018). 
Alternatively, the corresponding author would be more than happy to send over a more detailed document. 
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length of time for responding did not exceed 15 minutes. Limiting the number of changes 
allowed for more reliable cross-sectional comparisons between the 2012 and 2015 data. All 
questionnaires were translated into relevant sample languages by professional translators 
provided by Ipsos and double checked by the authors’ native language colleagues from 
academia and regulation. 
 
This paper reports on four sets of questions: (1) self-reported awareness and familiarity of 
national pharmaceutical regulatory authorities, (2) measures of trustworthiness, (3) behavioural 
intentions after personally receiving (e.g. via letter, telephone, e-mail etc.) information that 
points to potential safety problems with a medicine (i.e. ‘adverse information’), and (4) 
opinions on receiving medicines information (e.g. when the public should receive unverified 
potentially adverse information in the first place).  
 
Self-reported awareness and familiarity. Respondents were asked two self-reported knowledge 
questions about their relevant national-level regulatory body (although knowledge was not 
directly tested). First, “Have you heard of [relevant national-level regulator6]? (Yes/No)”. In 
2012, an additional ‘don’t know’ response option was included for this question but was 
removed in 2015. Second, respondents that said ‘Yes’ were asked: “How familiar or unfamiliar 
are you with [relevant national-level regulator]? (Very familiar, Fairly familiar, Not very 
familiar, Not at all familiar, Don’t know). 2015 respondents from Denmark were not asked 
either question because the agency changed its name less than one month before the survey 
was launched. To be clear, measures of respondents’ trust or perceived trustworthiness of these 
concrete pharmaceutical regulatory entities – such as the UK MHRA – were not made. This is 
                                                 
6 UK: MHRA (Medicines & Healthcare products Regulatory Agency); France: ANSM (L’Agence nationale de 
sécurité du médicament et des produits de santé); Germany: BfArM (Bundesinstitut für Arzneimittel und 




because previous surveys show that the vast majority of European citizens have not heard of 
either their supranational or national-level pharmaceutical regulators (although national 
variations have been found) (Bouder et al. 2015). 
 
Trustworthiness of medicines advice. Trustworthiness of multiple abstract entities was 
measured by asking respondents to rate 10 different sources of information that provide advice 
on medicine-related risks (i.e. side effects): “How trustworthy or untrustworthy do you believe 
the following sources are in providing you with advice on the side effects associated with 
specific medicines?” (Very trustworthy, Fairly trustworthy, Neither trustworthy nor 
untrustworthy, Not very trustworthy, Not at all trustworthy, Don’t know) [emphasis in 
original]. The sources of advice measured were: (1) General Practitioner (GP); (2) Local 
hospital; (3) Internet in general; (4) Brand specific websites (of specific medicines you may 
consider); (5) Media (e.g. newspapers, television, radio, etc.); (6) A friend or relative; (7) 
Pharmaceutical companies (including their websites); (8) Pharmacy, (9) Emergency services 
(e.g. 999)7; and (10) Medical journal. The ordering of sources was randomised between 
respondents. 
 
Behavioural intentions. A set of questions measured respondents’ medicine-taking and 
information seeking behavioural intentions after receiving potentially adverse information 
about a medicine they are taking. In both 2012 and 2015, respondents were asked: “If the 
information you personally receive (via letter, telephone, e-mail, etc.) points to potential safety 
problems with the medicine you are currently taking, do you think you are most likely to…” 
(1) Stop taking your medicine, (2) Reduce your dose of the medicine, (3) Continue taking your 
medicine as usual, (4) Seek additional advice about the medicine, or (5) Don’t know. Two 
                                                 
7 The telephone number for ’Emergency services’ varied between sample countries. 
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follow-up questions – that were not included in the 2012 survey – were also asked in 2015. 
Respondents that indicated option 1, 2, and 3 above were asked to clarify their medicine 
seeking intentions: “You say you are most likely to [stop/reduce/continue]. After/Whilst doing 
so, would you also seek additional advice about the medicine?” (Yes/No/Don’t Know). 
Alternatively, respondents that indicated option 4, were asked to clarify their medicine-taking 
intentions: “You say you are most likely to seek additional advice about the medicine. Whilst 
seeking advice, which of the following would you most likely do?” (1) Stop taking your 
medicine, (2) Reduce your dose of the medicine, (3) Continue taking you medicine as usual, 
or (4) Don’t know. The 2015 survey therefore enabled respondents to indicate a combination 
of medicine taking (i.e., ‘compliance’) and information seeking behavioural intentions. 
 
Opinions on receiving medicines information. Three constructs measured respondents’ 
opinions on receiving medicines information. One question asked about general opinions on 
receiving more medicines information: “Do you think that receiving more information about 
the safety of a medicine would increase your confidence in taking medicines?” (Yes/No/Don’t 
Know). Two questions asked about more specific opinions on when respondents would like to 
or think they should receive potentially adverse information on medicines. First, “Overall, do 
you think it is a good or bad idea to inform the general public about a potential medical safety 
problem with a medicine, before a scientific analysis has been undertaken? (By scientific 
analysis, we mean a full review of the available data by the regulators and pharmaceutical 
industry)” (Good idea, Bad idea, or Don’t know) [emphasis in original]. Second, “At what 
stage would you like information to be conveyed to you about a possible safety issue of a 
medicine that you use or may use?” (1) When there is a possible sign of a safety problem; (2) 
When the problem has been investigated and it is not clear if it is related to the medicine; (3) 
When the problem has been investigated and a pharmaceutical company believes it is related 
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to the medicine; (4) When the problem has been investigated and regulators believe it is related 
to the medicine; or (5) Don’t know. 
 
(2.3) Data analysis 
 
The 2012 and 2015 datasets were analysed using IBM SPSS Statistics in three stages. First, 
cross-sectional comparisons between the datasets were made to analyse changes over time in 
GB, France, and Germany. Second, cross-national comparisons were made between nations in 
the 2015 dataset (GB, France, Germany, Denmark, Italy, and Poland) (for 2012 cross-national 
comparisons see Bouder et al. 2015). Third, multivariate relationships between several 
variables – including trustworthiness and individuals’ behavioural intentions – were analysed 
in a structural equation model (using Mplus software). 
 
The first set of analyses compared variables across time between the 2012 and 2015 datasets. 
As this represents repeated cross-sectional data rather than longitudinal data from the same 
population (see Siegrist, 2014), we made comparisons: (1) via analysis of variance tests 
(ANOVAs) with post-hoc tests for pairwise comparisons and Bonferroni corrections for 
multiple comparisons, with nation as the factor variable – when the variable of interest is an 
interval variable, and (2) via chi-square significance in cross-tab tests when the variable of 
interest is categorical. 
 
The second set of analyses compared the 6 nations included in the 2015 survey. Again, this 
included comparing (1) knowledge of concrete pharmaceutical regulatory entities, (2) 
trustworthiness of medicines advice, (3) opinions on receiving medicines information, and (4) 
behavioral intentions (section 2.2). Where the variable of interest was an interval variable, 
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ANOVA tests were used. For variables of interest with multiple categorical response options, 
dummy variables representing each response option were generated, which were used as the 
dependent variable in a binary logistic generalised linear model with pairwise comparisons 
across nations and Bonferroni corrections. 
 
The third set of analyses sought to identify variables that predict behavioural intentions after 
personally receiving (e.g. via letter, telephone, e-mail etc.) information that points to potential 
safety problems with a medicine they are taking. Specifically, our dependent variable was 
propensity to continue taking the medicine whilst seeking additional information. The 
structural equation model allowed for simultaneous confirmatory factor analyses and 
regression pathways between the three latent variables (representing clusters of information 
sources) and the behavioural intention. The confirmatory factor analyses examined latent 
variables representing perceived trustworthiness in three groups of actors (specifically, 
medical, societal, and industry sources). Structural regression pathways were then included in 
the model that revealed direct effects of perceived trustworthiness in these actors on propensity 
to ‘continue and seek’. The model used a weighted least square mean and variance adjusted 





(3.1) Self-reported awareness and familiarity 
 
In 2015, the vast majority of respondents said ‘No’ they had not heard of their (relevant) 
national pharmaceutical regulatory authority in GB (78%), France (76%), Germany (85%), and 
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Poland (88%). Fewer respondents in Italy (61%) said ‘No’ they had not heard of theirs. Of 
those that said ‘Yes’ they had heard of their authority (N=1,117), over 50% in all five nations 
said they were ‘not very familiar’ or ‘not at all familiar’ with them: GB (71%), France, (61%), 
Germany (53%), Italy (52%), and Poland (56%). When combining awareness and familiarity 
questions, fewer than 8% of all respondents said they were either ‘very familiar’ or ‘fairly 
familiar’ with their authority in GB (6%), France (8%), Germany (7%), and Poland (6%), with 
marginally more indicating the same in Italy (18%). 
 
 (3.2) Trustworthiness of advice 
 
Public trustworthiness of sources of advice on side effects (associated with specific medicines) 
was measured with a battery of 9-10 questions (Section 2.2). An initial exploratory factor 
analysis (principal axis factoring, promax [oblique] rotation) pooled the 9 common sources of 
advice in the 2012 data into three factors that represented respondents’ trustworthiness of the 
following entities: 
 
1. Medical sources: general practitioner (GP), local hospital, pharmacy, and emergency 
services (e.g. 999); 
2. Societal sources: internet in general, mass media (e.g. newspapers, television, radio 
etc.), a friend or relative; 
3. Industry sources: pharmaceutical companies (and their websites), and brand specific 




Reliability scaling alpha values were: medical trust = 0.79, societal trust = 0.67 and industry 
trust = 0.81. The 2015 data included one additional source of advice not present in the 2012. 
We expected trustworthiness of ‘medical journals’ to pool with medical actors.   
 
Medical sources were the most trusted sources of advice in GB, France, and Germany in both 
2012 (mean of 3.93 on the five-point scale) and 2015 (mean of 3.95). Between 2012 and 2015, 
there were no significant differences for trustworthiness of medical sources within any nation 
(measured by an ANOVA with Bonferroni corrections; p < 0.05). Trustworthiness of societal 
sources increased significantly in France (+0.28) and Germany (+0.20) over time. 
Trustworthiness of industry sources increased in all nations, although industry trustworthiness 
was, notably, substantially lower on average than all other sources in both 2012 (2.44) and 
2015 (2.85). 
 
In 2015, trustworthiness of medical sources of advice was significantly higher in GB (3.98), 
France (3.89), and Denmark (3.94) than in Germany (3.78), Italy (3.75), and Poland (3.74) 
(measured by an ANOVA with Bonferroni corrections; p < 0.05.) (Figure 2). Trustworthiness 
of societal sources was the lowest in France (3.02) and GB (3.01) with France differing from 
all nations except GB, and GB having significantly less perceived trustworthiness of societal 
sources than Germany (3.19) and Poland (3.26). In 2015, trustworthiness of industry sources 
was significantly lower in France (2.68) and Germany (2.85) than all other nations, and 





Figure 2: Public trustworthiness of sources of medicines advice in 2015. 
 
(3.3) Behavioral intentions 
 
One question in 2012 and 2015 measured respondents’ behavioral intentions to receiving 
adverse information about a hypothetical medicine they are currently taking. Behavioral 
intentions includes behavior related to medicine-taking (i.e. continue to take the medicine as 
usual, reduce the dose of the medicine, or stop taking the medicine) and desire to seek 
information (or not) (section 2.2). After personally receiving adverse information (e.g. via 
letter, telephone, e-mail etc.) that points to potential safety problems with a medicine they are 
taking, the most popular behavioral intentions in both 2012 and 2015 were to either ‘seek 
additional advice about the medicine’ or ‘stop taking the medicine’ (Figure 3). Between 2012 
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medicine’ changed significantly in all nations. While seeking intentions increased in the case 
of Germany (+10%) – reflecting a concomitant decrease in respondents indicting they would 
stop taking their medicine (-15%) –, they decreased in GB (-4%) and France (-13%) (significant 
differences measured by a chi-square significance for a cross-tab test; p < 0.05). Respondents 
from GB were also found to be significantly more likely to seek additional advice about the 
medicine than respondents from Germany and France in both 2012 and 2015, while 
respondents from Germany and France were significantly more likely to stop taking their 
medicine (Figure 3). 
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In 2015, two follow-up questions were asked that enabled respondents to indicate both their 
medicine-taking intentions (i.e. continue, reduce or stop) and desire to seek information (or 
not) (section 2.3). By combining all three questions, the percentages in Figure 4 were created. 
The plurality of respondents from each nation indicated that if respondents received 
information pointing to potential safety problems with their medicine they are currently taking, 
they would either (1) stop taking their medicine and seek more information (i.e. “stoppers”) or 
(2) continue taking their medicine as usual whilst seeking more information (i.e. “continuers”). 
Stark differences between 2015 nations were identified. Respondents from GB and Denmark 
were far more likely to continue taking their medicine as usual whilst seeking additional advice 
than any other option (continuers). In contrast, respondents from France, Germany, Italy, and 
Poland were all inclined to stop taking their medicine whilst seeking information (stoppers) 






Figure 4: Combined data on the public’s medicine-taking and information seeking behavioral 
intentions after receiving potentially adverse medicines information. 
 
(3.4) Opinions on receiving information.  
 
Two questions measured opinions on receiving medicines information ranging from general to 
more specific constructs. First, the vast majority of respondents in 2012 (71%) and 2015 (76%) 
indicated that receiving more information (in general) about the safety of a medicine would 
increase their confidence in taking medicines (Table I). In 2015, Demark (65%) had the fewest 
answering ‘Yes’ more information would increase their confidence in taking medicines, while 
Italy (85%) and Poland (81%) had the most (significant differences measured by binary logistic 
generalised linear models with Bonferroni corrections). Second, 59% of respondents in 2015 
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safety problem with a medicine before a scientific analysis has been undertaken by the 
regulators and the pharmaceutical industry (Table II). National variations ranged from 52% in 
GB and Denmark to 69% in Poland indicating it is a good idea. 
  
Table I: Do you think that receiving more information about the safety of a medicine would 
increase your confidence in taking medicines? Numbers in cells represent percentages; 
superscript letters that vary within a question denote statistically significant differences (p < 
0.05, with Bonferroni corrections); statistical differences only presented for the first option in 
each question 
 GB France Germany Denmark Italy Poland 
Yes 73a 78a,b 75a 65c 85d 81b,d 
No 12 12 11 15 6 8 
Don’t know 15 10 13 19 9 11 
 
Table II: Overall, do you think it is a good or bad idea to inform the general public 
about a potential medical safety problem with a medicine, before a scientific analysis 
has been undertaken? 
 GB France Germany Denmark Italy Poland 
Good idea 52a 58a,b 59b 52a 63b 69c 
Bad idea 28 25 23 27 23 17 
Don’t know 20 17 18 21 15 13 
 
Complementing results from these three general questions, a fourth, more specific, question 
measuring opinions on receiving uncertain adverse medicines information asked at what stage 
respondents would like information to be conveyed to them about a possible safety issue with 
a medicine they use or may use (section 2.2). In all nations, respondents in both 2012 (58%) 
and 2015 (55%) indicated they would like this information ‘when there is a possible sign of a 
safety problem’ rather than ‘when the problem has been investigated and it is not clear if it is 
related to the medicine’, ‘when the problem has been investigated and a pharmaceutical 
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company believes it is related to the medicine’, or ‘when the problem has been investigated 
and regulators believe it is related to the medicine’ as well as those that indicated ‘don’t know’ 
(Figure 3). This most popular response reduced over time in Germany (-7%) (Figure 5) with 
significantly more respondents indicating ‘when the problem has been investigated and it is not 
clear if it is related to the medicine’ (measured by a chi-square significance for a cross-tab test, 
p < 0.05). In 2015, few major differences emerged between nations (Figure 5).  
 
 
Figure 5: Opinions on when information on a potential safety issue should be given to the 
public 
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A structural equation model examined the capacity for trust in information sources to predict 
respondents’ behavioral intentions (Figure 7) (section 3.4).8 Specifically, the model examined  
trust’s relation to intentions to ‘continue to take their medicine whilst seeking additional 
information’ (hereafter, ‘continue and seek’ behaviour), that is, in a scenario where they 
received (e.g. via letter, telephone, e-mail etc.) information that points to potential safety 
problems with the medicine they are currently taking (see section 3.3). Confirmatory factor 
analyses were conducted whilst regressing the latent and measured variables on each other. 
The dependent variable of interest was a dichotomous variable: whether a respondent selected 
the behaviour of continue and seek or not. The confirmatory factor analysis was specified to 
generate the three latent factors identified in section 3.2: trustworthiness of medical, societal, 
and industry sources of advice about the side effects associated with specific medicines. All 
coefficients on pathways in Figure 7 represent either factor loadings (on arrows from measures 
of trustworthiness to the latent factors) or unstandardised regression coefficients (on all other 
arrows). The model explored the effect of the following on the dependent variable:  
(1) direct effects from the latent variables representing trustworthiness (i.e. medical, 
societal, and industry sources of advice; H1 – H3), and  
(2) age (measured linearly in years) and sex (with ‘male’ as the reference category).  
 
The model had adequate to good fit (RMSEA = 0.048 [90% confidence interval of 0.045-
0.050], CFI = 0.94, Chi-Square = 845 with 58 d.f.). Trustworthiness of medical sources of 
advice strongly (0.50) directly predicted ‘continue and seek’ behaviour (H1 supported). 
Meanwhile, trustworthiness of societal (-0.48) sources directly reduced the likelihood of 
                                                 
8 We used the default setting in Mplus for structural equation models with binary outcome variables, which 
utilises multivariate probit regressions and a robust weighted least squares estimator. 
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continue and seek behaviour (H2 supported).  There was no statistically significant relationship 
between industry sources and the behavioural intention (H3 not supported). Age and sex both 
exerted an additional direct effect on continue and seek behaviour (‘seek and continue’ more 





Figure 7: Structural equation model predicting respondents’ behavioural intentions to ‘continue to take their medicine as usual whilst seeking 
additional information’ (i.e. ‘continue and seek’), if they received information that points to potential safety problems with the medicine they are 
currently taking. *variables with an asterisk measure perceived trustworthiness of the entity listed. N.B. All factor loading and parameter 








In the ‘New Transparency Era’ a strong emphasis has been placed on building public trust in 
medicines and the pharmaceutical evaluation system (Way, 2017). This study examined the 
relationship between the public’s perceived trustworthiness of various medical, societal, and 
industry sources of advice on side effects and its consequences for behavioural intentions and 
public opinion, specifically, in a scenario where the public were to receive information pointing 
to potential safety problems with their medicine(s).   
 
(4.1) Trustworthiness and its consequences 
 
The study had four main findings. First, medical sources of advice (GPs, local hospitals, 
pharmacies, emergency services, and medical journals) were perceived as more trustworthy 
than societal and especially industry sources in all countries surveyed. In conjunction, all of 
these medical sources pooled together on factors analyses of the 2012 and 2015 data. This is 
consistent with past studies showing that the European public have high levels of trust in 
healthcare professionals and relatively low trust in pharmaceutical companies. For example, 
annual nationally representative polls conducted by Ipsos MORI between 1993 and 2015 show 
that, compared with a total of 24 professions, medical doctors have consistently been perceived 
as the most trusted professionals in Europe followed by teachers, judges, and scientists (Ipsos, 
2016). Results from the present study are also consistent with findings that the pharmaceutical 
industry have relatively low levels of trust in Europe (albeit not as low as in the US) (Löfstedt, 
2007; Löfstedt et al. 2011). For example, a survey by YouGov (2016), a UK polling agency, 






Second, a structural equation model revealed a particularly strong positive relationship (0.50) 
between the public’s perceived trustworthiness of medical sources (GPs, local hospitals, 
pharmacies, emergency services, and medical journals) and intentions to continue taking their 
medicines as usual whilst seeking additional advice, if they received information pointing to 
potential safety problems with a medicine they are currently taking. This behaviour is what 
would be recommended by the regulators and healthcare professionals in such a scenario with 
NHS Choices (2019), the official health website of the UK National Health Service, making 
clear that patients should “…only ever stop taking prescribed medication if your GP 
specifically advises you to”. Trust in societal sources had an equally strong effect, but in the 
opposite direction – higher societal trust made compliance less likely (-0.48). 
 
Third, stark national variations were found in the type of behaviour the public intend to engage 
in after receiving potentially adverse medicines information. Respondents from GB and 
Denmark were far more likely than all other sample countries to indicate that they would 
continue taking their medicine as usual whilst seeking additional advice than any other option 
(‘the continuers’). In contrast, respondents from France, Germany, Italy, and Poland were far 
more inclined to stop taking their medicine whilst seeking additional advice (‘the stoppers’) 
(40-43%). Continuer countries also rated medical sources as more trustworthy than stopper 
countries reflecting the strong medical source trust-behaviour relation. The divide between two 
distinct groups of continuers and seekers is also consistent with findings from Bouder et al. 
(2015), which identified clear national variations between “stoppers” (Germany, France, and 
Spain) and “seekers” (GB, Sweden, the Netherlands). 
 
Fourth, the public self-reported low levels of knowledge of the regulators. The large majority 





they had not heard of the concrete entities that regulate pharmaceuticals in their respective 
nations. Furthermore, the majority who said they had heard of them also indicated that they 
were ‘not very’ or ‘not at all’ familiar with the regulators. Considering respondents were asked 
self-reported knowledge questions that are vulnerable to social desirability bias (Fisher, 1993), 
the public’s knowledge of relevant national authorities is also likely to be lower than these 
findings suggest. 
 
The results have at least three main limitations. First, only one quantitative examination on 
trustworthiness and its consequences was examined. Risk communication scholars have 
emphasised the importance of measuring trust in a variety of ways by using a mix of both 
qualitative and quantitative methods (Pidgeon et al. 2007; Siegrist, 2010). This includes asking 
respondents to make different judgements of trust (or trustworthiness) that vary depending on 
the target, tangibility, type, and referent of judgement (Earle et al. 2007: 22). Findings from the 
present study therefore need to be compared with future studies using other measures of 
trust/trustworthiness in the understudied European pharmaceutical context. Second, 
respondents were asked questions about their intentions to engage in behaviour and opinions 
relating to medicines in general. The benefits and risks of medicines vary significantly 
depending on what they seek to treat (e.g. headaches, HIV/AIDS, multiple sclerosis, acne, etc.). 
Individuals may therefore have different behavioural intentions after receiving potentially 
adverse information depending on (a) what that information specifically says, and (b) what 
medicine it refers to. With that said, a survey (Way et al. 2016) of individuals diagnosed with 
various specific medical conditions found very similar results to those reported in the present 
study. Third, two cross-sectional datasets were analysed. A longitudinal study design would be 






(4.2) Implications for trust research 
 
The first main implication of this study is that risk perception and communication researchers 
need to pay careful attention to the specific real-world risk context they are investigating when 
conducting trust research. The study identified a range of contextual factors that distinguish the 
(European) pharmaceutical context from other risk domains. One feature that distinguishes 
pharmaceuticals is that there is a remarkable lack of public knowledge about the concrete 
entities that regulate medicines and the underlying pharmaceutical regulatory system in 
Europe. In turn, this has important implications for who the public trust and seek information 
from to inform their medical decision-making. A second important feature is that, in lieu of 
knowing who regulates medicines, the public use a variety of information sources or 
‘communication channels’ to inform their decision-making. This includes various medical, 
societal and industry sources of information. A third important feature is that there are clear 
differences between how the public are likely to react to new information on medicines 
between European countries. For example, while patients in some countries are more likely to 
continue taking their medicine if they receive adverse information, such as GB and Denmark, 
patients in other countries are more likely to stop taking their medicines, such as Germany and 
Poland. This has important implications for how benefits and risks are communicated in 
different national contexts. This study therefore furthers the conclusion from the trust literature 
that there are critical differences between risk management domains and countries (Löfstedt, 
2005) and that the pharmaceutical domain is no exception.  
 
A second main implication of this study for trust research is that concerted efforts need to be 
made to reduce fragmentation between the various fields risk perception and risk 





dominated by investigations into environmental/ technological risks and, more recently, food 
safety issues (Way, 2017). In contrast, trust research in the pharmaceutical domain, has been 
largely disconnected from the environmental/ technological and food safety fields (Löfstedt 
and Perri 6, 2008). While this study highlighted key distinguishing features about the 
pharmaceutical domain, many of the challenges facing pharmaceutical risk regulators and 
communicators identified in this study are shared by risk regulators and communicators in other 
areas. Although there are some benefits of fragmentation, there is much more that can be done 
to cross-fertilise methods, findings and tools between different fields of trust research.  
 
On the one hand, the medical/ pharmaceutical field could learn a great deal from over fifty 
years of experience from the environmental/ technological fields. While research on patient-
doctor decision-making remains important in the medical context, the pharmaceutical 
information and communication environment has changed dramatically over the past twenty-
five years (Way, 2017: 18). As this study showed, patients now obtain information from a wide 
variety of information sources beyond the doctor’s office, some of which are more trusted than 
others. This is creating new challenges for pharmaceutical risk regulators and communicators 
many of which are well-known by environmental/ technological researchers and practitioners. 
For example, Kasperson and Stallen (1991) illustrate how the environmental/ technological 
fields of risk perception and communication have had a long history, with the nuclear power 
field emanating from 1950s public perceptions of nuclear power risk. The wealth of findings, 
methods and approaches from other fields could therefore be tested in the new pharmaceutical 
information environment.  
 
On the other hand, the environmental/ technological and food safety fields could learn from 





communication research has centred on the role of trust in patient-doctor decision-making 
(Mallia, 2013; Holt et al. 2016). An abundance of cutting-edge research has emanated from 
this research programme including on interpersonal relations between doctors, patients and 
other healthcare professionals. Indeed, doctors play a central role in communicating benefits 
and risks directly to patients and so are typically intimately involved in decision-making (Holt 
et al. 2016). Much research has also investigated how patients make medical judgements and 
decisions in a context where the benefits and risks affect them directly. A great deal of research 
from the pharmaceutical/ medical domain could therefore be tested in other fields in order to 
tackle some of the biggest challenges facing risk regulators and communicators.  
 
(4.3) Implications for pharmaceutical regulation 
 
What do these contextually-relevant results on trust imply for European pharmaceutical 
regulators? It is not yet clear what the full extent of EMA’s transparency policies and the 
broader trend towards more data transparency will be for the public, as well as their trust in the 
pharmaceutical evaluation system. What is clear though is that the medicines information 
environment has changed with evidence that the public have begun to receive more disputed 
and conflicting information pointing to potential safety problems with their medicines through 
various information channels (Section 3.1). There is also clear evidence that this is not a 
hypothetical scenario (e.g. Butler, 2014; Burki, 2018). On the one hand, this trend may be 
short-lived. Future negative re-analyses may not be as widely publicised as they have over the 
past few years. While Ebrahim et al. (2014) found that there have been surprisingly few re-
analyses conducted compared to those that could have been, EMA expect that the ‘real’ risk 
with issues around data transparency is low (personal communication, 2014). The agency also 





clinical data on its web-portal (EMA, 2018b), showing that there are important resource 
constraints to transparency (Way, 2017).  
 
On the other hand, the number of re-analyses that point to potential safety problems may 
continue and, indeed, even increase over time (see O’Neill, 2006 for a theoretical discussion; 
Manson and O’Neill, 2007: 90). This latter scenario seems much more likely after (1) 
researchers become more aware of the data that is increasingly available and more sophisticated 
in analysing such large datasets (Doshi et al. 2013; Ebrahim et al. 2014), (2) the EMA’s policies 
come into full effect and (3) the new clinical trial regulation comes fully into force providing 
outsides with even greater and unprecedented access to previously unavailable datasets 
(Clinical Trial Regulation [CTR] EU No. 536/2014). Indeed, a central trust-related goal of 
EMA’s policies is to enable external re-analysis (Chan et al. 2014; Bonini, 2014), which means 
that the goal is precisely to encourage more re-analyses of regulatory data, something which 
pharmaceutical regulators themselves have been encouraging (Eichler et al. 2013). In this 
context, the result of this study has several important implications for the future of 
pharmaceutical regulation. 
 
(4.3.1) Maintain and strengthen trust in medical actors 
 
The first implication is that the regulators need to make concerted efforts to maintain and 
strengthen public trust in medical sources of advice in the new transparency era (i.e. GPs, 
pharmacists, local hospitals, medical journals, and emergency services) (Löfstedt, 2005, 2007). 
The study found that if the public receive more information pointing to safety problems with 
their medicine (e.g. originating or mediated from ‘independent’ re-analyses) then the level of 





continue taking their medicine as usual whilst seeking additional advice about the problem. If 
the goal is to persuade the public to adopt this recommended advice (NHS Choices, 2019), then 
it is critically important to maintain the public’s currently high levels of trust in medical 
sources. Vice versa, if this trust is not maintained in a more transparent environment, then the 
trust-consequence relationship found in this study would strongly suggest that there will be a 
downfall in prescription compliance (also see Bouder et al. 2015). In particular, in “stopper” 
countries (i.e. Germany, France, Poland, and Italy) compared to “continuer” countries 
(Denmark and GB), there is a need to maintain but, moreover, strengthen public trust in medical 
sources to avoid poor prescription compliance. Indeed, public trustworthiness of medical 
sources was rated as significantly higher in this 2015 study in GB and Denmark (the continuers) 
than in France, Germany, Italy, and Poland (the stoppers) (Figure 4). Furthermore, the fact that 
a variety of medical sources pooled together on the factor analyses of the 2012 and 2015 data 
(i.e. GPs, pharmacists, local hospitals, medical journals, and emergency services) means that 
there are a variety of medical actor avenues that the regulators can target for building trust and 
communicating benefit-risk with the public. 
 
(4.3.2) Commit more resources to supporting national risk communication 
 
The second implication is that, if public trust is to be maintained and strengthened, then EMA 
will have to commit more resources to supporting national authorities in a more transparent 
environment. Echoing previous studies, this study found that the large majority of European 
citizens have not heard of the regulators and, those that say they have, are unfamiliar with them. 
The European public also do not directly receive – or knowingly receive (e.g. patient leaflets) 
– benefit-risk information from pharmaceutical regulators. Rather, benefit-risk information is 





and information channels between various institutions, groups, and individuals (Pidgeon et al. 
2003; Van Asselt and Renn, 2011). Along with identifying clear national variations, it is 
therefore apparent that EMA will have to work closely with national authorities that have 
intimate localised knowledge of national healthcare systems. This includes an in-depth 
understanding of the actors that are at the coal-face of communicating benefit-risk information 
with the public and, as this study shows, who are critical for maintaining public trust in the 
pharmaceutical system. In so doing, one goal will be to improve doctors’ understanding of the 
benefit-risk evaluation system. Past studies show that medical doctors are ill-equipped, 
especially in terms of time and resources, to deal with complicated questions from patients 
about the intricacies of the medicines evaluation system (British Medical Association, 2016; 
Löfstedt et al. 2016). This is therefore one notable issue that needs to be addressed if the 
regulators’ transparency and trust-building goals are to be achieved.  
 
(4.3.3) Test for public trust across Europe 
 
The third implication is that EMA and member state regulators need to test for trust not just in 
their institutions but, perhaps more importantly, in the various medical, societal, and industry 
actors from whom the public obtain mediated benefit-risk information. Testing for trust can 
help to guide the regulators’ risk communication efforts and resources (Morgan et al. 2002; 
Löfstedt, 2005). In particular, it can provide a better understanding of what stakeholders and 
citizens need in terms of communication. Past studies have shown that if there are high levels 
of public trust then top down forms of communication may be acceptable (Löfstedt, 2005). 
However, if there is a lack of trust (because citizens see the regulators as incompetent) then the 
regulators will need to address that issue by hiring more competent civil servants and 





those that are at the coal-face of communicating with the public (e.g. GPs, pharmacists, etc.) 
therefore means that the regulators need to closely examine public trust in them in order to be 
successful in the new transparency era. In so doing, this 2015 survey and that of Bouder et al. 
(2015) conducted in 2012 can provide a useful benchmark for the regulators. However, these 
studies examined a total of 9 EU countries and therefore do not reveal public perceived 
trustworthiness in all 28 member states as well as European Economic Area countries, Iceland, 
Lichtenstein, and Norway for whom the European regulators are responsible. Testing for trust 
across all EU nations therefore would be a critically important first step for communicating 
benefits and risk in the new transparency era (see Löfstedt, 2005; Earle, 2010 and Siegrist, 




This cross-sectional survey study of six EU nations measured the relationship between the 
public’s trustworthiness of different sources of medicines advice and its consequences for their 
behavioural intentions and opinions in a scenario where they have received potentially adverse 
medicines information. Several strong, moderate and weak relationships were found and the 
most important implications of the study’s findings for the regulators were discussed. This is 
particularly important since pharmaceutical regulators have sought to use information 
disclosure as a way to (re)gain public trust. The study provides a platform for future studies on 
trust and risk perception in the pharmaceutical context that can help to inform the regulator’s 
future policies. The findings particularly emphasise the importance of testing for trust in a more 
transparent environment. It would be easy to underemphasise the need to conduct more 
quantitative and qualitative studies on trust to test these results and explore other trust issues in 





in such an understudied context, especially considering there are important policy implications 
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Appendix A: 2015 sample demographics (see Bouder et al. 2015 for data on the 2013 
survey) 
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54 
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9.20 9.22 9.50 9.52 
      
Denmark 18–
24 
7.50 7.55 7.20 7.25 
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34 
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44 
11.20 11.19 11.10 11.09 
45–
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France 18–
24 
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45–
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55–
64 
10.20 10.18 10.90 10.90 
      
Germany 18–
24 







9.90 9.93 9.60 9.55 
35–
44 
10.60 10.57 10.20 10.20 
45–
54 
13.60 13.47 13.00 13.02 
55–
64 
10.20 10.20 10.40 10.45 
      
Italy 18–
24 
5.90 5.86 5.60 5.58 
25–
34 
9.40 9.42 9.40 9.37 
35–
44 
12.50 12.45 12.50 12.54 
45–
54 
12.10 12.13 12.50 12.52 
55–
64 
9.70 9.73 10.40 10.41 
      
Poland 18–
24 
7.10 7.16 6.90 6.88 
25–
34 
12.40 12.38 12.00 12.02 
35–
44 
10.50 10.53 10.30 10.30 
45–
54 
9.70 9.72 9.90 9.87 
55–
64 
10.00 9.99 11.20 11.16 
 





Country Region Eurostat (2013) 2015 Survey 
GB North East 4.18 4.20 




West Midlands 8.92 8.90 
East Midlands 7.31 7.20 
East of England 9.33 9.30 
South West 8.33 8.30 
South East 13.84 13.90 
Greater London 14.65 14.70 
Wales 4.84 4.80 
Scotland 8.74 8.90 
    
Denmark Hovedstaden (Capital 












of Southern Denmark) 
21.00 20.94 
    
France Region Parisienne 19.80 19.73 
Nord-Ouest 22.40 22.41 
Nord-Est 22.60 22.68 
Sud-Ouest 10.80 10.83 
Sud-Est 24.40 24.35 
    





Nielsen II 21.70 21.67 
Nielsen IIIa 13.60 13.58 
Nielsen IIIb 13.40 13.27 
Nielsen IV 15.60 15.56 
Nielsen V (a&b) 4.50 4.54 
Nielsen VI 7.60 7.83 
Nielsen VII 7.60 7.60 
    
Italy Nord-ovest 26.10 26.23 
Nord-est 19.20 19.14 
Centro (I) 19.50 19.45 
Sud 23.90 23.86 
Isole 11.30 11.32 
    
Poland Region centralny 
(Central region) 20.40 20.05 
Region poludniowy 
(Southern region) 20.80 20.68 
Region wschodni 
(Eastern region) 17.40 17.38 
Region pólnocno-
zachodni (North-
western region) 16.30 16.28 
Region poludniowo-
zachodni (South-
western region) 10.50 10.39 
Region pólnocny 
(North region) 14.60 15.22 
 
Table V: 2015 data: Working/not working for GB, Denmark, and France 
 


















Working 73 73 74 74 67 67 
Not 
working 
27 27 26 26 33 33 
 
Table VI: 2015 data: Working/not working for German, Italy, and Poland 
 














Working 76 76 58 58 63 64 
Not 
working 
24 24 42 42 37 36 
 
Appendix B: Final 2015 questionnaire 
 
1. How easy or difficult is it for you to obtain information about medicines from each of the following 
sources?  
 
Please choose one answer per row 
 
ACROSS THE TOP 
1. Very easy 
2. Somewhat easy 
3. Neither easy nor difficult 
4. Somewhat difficult 
5. Very difficult 
6. Don’t know 
 
DOWN THE SIDE (RANDOMISE ORDER – CODES 7 AND 8 ALWAYS TOGETHER AND 
CONSECUTIVE) 
1. General Practitioner (GP) 
2.  





4. Internet in general 
5. Brand specific websites (of specific medicines you may consider) 
6. Media (e.g. newspapers, television, radio, etc.) 
7. A medically qualified friend or relative 
8. Another friend or relative (not medically qualified) 
9. Pharmaceutical companies (including their websites) 
10. Pharmacy 
11. Emergency services (e.g. <DIFFERENT TEXT BASED ON NATION: GB=999 / ALL 
OTHERS=112>) 
12.   Medical journal 
13.   Groups representing patients 
 
2. At what stage would you like information to be conveyed to you about a possible safety issue of a 
medicine that you use or may use?  
 
Please choose one answer only 
 
1. When there is a possible sign of a safety problem 
2. When the problem has been investigated and it is not clear if it is related to the medicine 
3. When the problem has been investigated and a pharmaceutical company believes it is related to the 
medicine 
4. When the problem has been investigated and regulators believe it is related to the medicine  
5. Don’t know  
 
3. Do you think that receiving more information about the safety of a medicine would increase your 
confidence in taking medicines? 
 




3. Don’t know 
 
4. If the information you personally receive (via letter, telephone, e-mail, etc.) points to potential 






Please choose one answer only 
 
1. Stop taking your medicine 
2. Reduce your dose of the medicine  
3. Continue taking your medicine as usual 
4. Seek additional advice about the medicine 
5. Don’t know   
 
4(a). You say you are most likely to <INSERT ANSWER GIVEN AT Q5 IN LOWER CASE>. 
<INSERT “After” IF Q5=1 OR 2 / “Whilst” IF Q5=3 > doing so, would you also seek additional 
advice about the medicine? 
 
4(b). You say you are most likely to <INSERT ANSWER GIVEN AT Q5 IN LOWER CASE> . 
While seeking additional advice, which of the following are you most likely to do? 
 
Please choose one answer only 
 
1. Stop taking you medicine  
2. Reduce your dose of the medicine 
3. Continue taking your medicine as usual 
4. Don’t know 
 
 
5. At what stage do you think that members of the general public should be informed about a potential 
medical safety problem with a medicine? 
 
Please choose one answer only 
  
1. As soon as a potential medical safety problem has been identified and before scientific analysis is 
complete to confirm whether or not there is a problem 
2. After scientific analysis has been undertaken and the scientific analysis has confirmed there is a 
problem 






6. How trustworthy or untrustworthy do you believe the following sources are in providing you with 
advice on the side effects associated with specific medicines? 
 
Please choose one answer per row 
 
ACROSS THE TOP 
1. Very trustworthy 
2. Fairly trustworthy 
3. Neither trustworthy nor untrustworthy 
4. Not very trustworthy 
5. Not at all trustworthy 
6. Don’t know 
 
DOWN THE SIDE (RANDOMISE ORDER – CODES 7 AND 8 ALWAYS TOGETHER AND 
CONSECUTIVES) 
1. General Practitioner (GP) 
2.  
3. Local hospital 
4. Internet in general 
5. Brand specific websites (of specific medicines you may consider) 
6. Media (e.g. newspapers, television, radio, etc.) 
7. A medically qualified friend or relative 
8. Another friend or relative (not medically qualified) 
9. Pharmaceutical companies (including their websites) 
10. Pharmacy 
11. Emergency services (e.g. <DIFFERENT TEXT BASED ON MARKET: GB=999 / ALL 
OTHERS=112>) 
12.   Medical journal 
13.   Groups representing patients 
 
7. Overall, do you think it is a good or bad idea to inform the general public about a potential medical 
safety problem with a medicine, before a scientific analysis has been undertaken? (By scientific 
analysis, we mean a full review of the available data by the regulators and pharmaceutical industry) 
 






1. Good idea 
2. Bad idea 
3. Don’t know 
 
8(a). Have you heard of <INSERT TEXT BASED ON MARKET: GB=MHRA / 
DENMARK=DKMA / FRANCE= l’ANSM / GERMANY=BfArM / ITALY=AIFA / 
POLAND=URPL>? 
 
Please choose one answer only 
 
1. Yes  
2. No  
 
8(b). In only a few words, what do you think <INSERT TEXT BASED ON MARKET: 
GB=MHRA/ DENMARK=DKMA / FRANCE= l’ANSM / GERMANY=BfArM / ITALY=AIFA / 
POLAND=URPL > do? 
 
8(c). You said that you had heard of the below agency. How familiar or unfamiliar are you with each 
of those agencies?  
 
Please choose one answer per row 
 
ACROSS THE TOP 
1. Very familiar 
2. Fairly familiar 
3. Not very familiar 
4. Not at all familiar 
5. Don’t know 
 
Appendix C: 2015 survey response rates 
  GB France Germany Denmark Italy Poland 









/overall) 448 740 378 346 671 831 
Screened out 
for other 
reasons 11 21 20 14 7 9 
Terminated/ 
abandoned 78 88 63 97 51 100 
Completed 
interview  1000 1000 1000 1001 1000 1000 
Response 
rate  10.8% 13.3% 14.6% 8.5% 26.1% 10.4% 
 
 
